PriceTargets.com logo

OTCMKTS:ANTH - Anthera Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.02 As of 09/27/2021 01:00 AM ET
+0.30 (1.20%)

This chart shows the closing price for ANTH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Anthera Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ANTH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ANTH

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Anthera Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.02.

This chart shows the closing price for ANTH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Anthera Pharmaceuticals. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/5/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/4/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/2/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/31/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/31/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/15/2018Jefferies Financial GroupReiterated RatingHold$0.50
3/12/2018Piper Jaffray CompaniesDowngradeOverweight ➝ Underweight
3/6/2018HC WainwrightReiterated RatingBuy
2/21/2018Roth CapitalInitiated CoverageBuy ➝ Buy$10.00 ➝ $10.00
9/19/2017HC WainwrightReiterated RatingBuy$3.00
8/11/2017Jefferies Financial GroupReiterated RatingHold$2.25 ➝ $1.75
5/15/2017Jefferies Financial GroupReiterated RatingHold$2.25
3/6/2017Jefferies Financial GroupLower Price TargetHold$8.00 ➝ $6.40
12/29/2016Piper Jaffray CompaniesLower Price TargetOverweight$56.00 ➝ $10.80
12/29/2016Jefferies Financial GroupDowngradeBuy ➝ Hold$40.00 ➝ $8.00
12/29/2016CitigroupDowngradeBuy ➝ Neutral
12/29/2016HC WainwrightReiterated RatingBuy$80.00 ➝ $24.00
12/28/2016SunTrust BanksDowngradeBuy ➝ Hold$48.00 ➝ $8.00
(Data available from 9/27/2016 forward)

News Sentiment Rating

0.98 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/1/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/31/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/30/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/30/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/29/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/29/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/28/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/27/2021

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Anthera Pharmaceuticals logo
Anthera Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of medicines to treat serious and life threatening diseases. It offers Sollpura and blisibimod to treat diseases such as exocrine pancreatic insufficiency and Immunoglobulin A nephropathy. The company was founded by Paul F. Truex on September 9, 2004 and is headquartered in Hayward, CA.
Read More

Today's Range

Now: $0.02
Low: $0.02
High: $0.02

50 Day Range

MA: $0.03
Low: $0.00
High: $0.06

52 Week Range

Now: $0.02
Low: $0.00
High: $0.19

Volume

4,700 shs

Average Volume

122,405 shs

Market Capitalization

$115,000.00

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.92

Frequently Asked Questions

What sell-side analysts currently cover shares of Anthera Pharmaceuticals?

The following sell-side analysts have issued reports on Anthera Pharmaceuticals in the last year:
View the latest analyst ratings for ANTH.

What is the current price target for Anthera Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Anthera Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Anthera Pharmaceuticals in the next year.
View the latest price targets for ANTH.

What is the current consensus analyst rating for Anthera Pharmaceuticals?

Anthera Pharmaceuticals currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for ANTH.

How do I contact Anthera Pharmaceuticals' investor relations team?

Anthera Pharmaceuticals' physical mailing address is 25801 INDUSTRIAL BOULEVARD SUITE B, HAYWARD CA, 94545. The biopharmaceutical company's listed phone number is (510) 856-5600. The official website for Anthera Pharmaceuticals is www.anthera.com.